795306-90-0

Upstream product

• 795306-89-7 (2S,3R)-3-(4-benzyloxyphenyl)-3-(4-fluorophenyl)-2-hydroxypropionic acid methyl ester 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 795306-88-6 (3S,4R)-2-(4-benzyloxyphenyl)-1-(4-fluorophenyl)-3-hydroxyazetidin-2-one 
• 1206694-75-8 4-(2-aza-2-(4-fluorophenyl)vinyl)-1-benzyloxybenzene 
• 795306-87-5 (2S,5R,6S)-2-[(2R,3S)-2-(4-benzyloxyphenyl)-1-(4-fluorophenyl)-4-oxocyclobutoxy]-2,4,5-trimethyl-6-phenylmorpholin-3-one 

Downstream Products

• 795306-91-1 (4R,5S)-4-(4-benzyloxyphenyl)-3-(4-fluorophenyl)-2-hydroxymethyloxazolidin-2-one 
• 869588-19-2 (4R,5R)-4-(4-benzyloxyphenyl)-3-(4-fluorophenyl)-5-[(E)-3-(4-fluorophenyl)-3-oxopropenyl]oxazolidin-2-one 
• 869588-20-5 (4R,5R)-4-(4-Benzyloxy-phenyl)-3-(4-fluoro-phenyl)-5-[3-(4-fluoro-phenyl)-3-oxo-propyl]-oxazolidin-2-one 

Relevant academic research and scientific papers

Heterocyclic ring scaffolds as small-molecule cholesterol absorption inhibitors

Enantio- and diastereoselective syntheses of a substituted oxazolidinone, isoxazoline and pyrazoline as β-lactam surrogates are described. The substituted heterocycles were designed to incorporate side chains closely resembling those found in the β-lactam cholesterol absorption inhibitor ezetimibe (1). Additionally, the in vitro inhibitory efficacy of the novel compounds as cholesterol absorption inhibitors is reported using a brush border membrane vesicle assay. The Royal Society of Chemistry 2005.